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PURPOSE. A mouse model of age-related macular degeneration (AMD) was used to investigate
the anti-angiogenic and anti-inflammatory role of UPARANT in laser-induced choroidal
neovascularization (CNV).
METHODS. Choroidal neovascularization was induced by laser photocoagulation, and
UPARANT was intravitreally injected. Some experiments were also performed after either
intravitreal injection of anti-VEGF drugs or systemic administration of UPARANT. Immuno-
histochemistry using CD31 antibodies was used to evaluate the area of CNV. Evans blue dye
extravasation was quantitatively assessed. Transcripts of markers of outer blood retinal barrier
were measured by quantitative RT-PCR, also used to evaluate angiogenesis and inflammation
markers. Western blot was used to determine levels of transcription factors encoding genes
involved in angiogenesis and inflammation. Levels of urokinase-type plasminogen activator
(uPA), its receptor (uPAR), and formyl peptide receptors (FPRs) were determined at the
transcript and the protein level.
RESULTS. Intravitreal UPARANT reduced the CNV area and the leakage from the choroid. The
uPA/uPAR/FPR system was upregulated in CNV, but was not influenced by UPARANT.
UPARANT recovered laser-induced upregulation of transcription factors encoding angio-
genic and inflammatory markers. Accordingly, angiogenic and inflammatory factors were
also reduced. UPARANT as compared to anti-VEGF drugs displayed similar effects on CNV
area.
CONCLUSIONS. UPARANT mitigates laser-induced CNV by inhibiting angiogenesis and
inflammation through an action on transcription factors encoding angiogenesis and
inflammatory genes. The finding that UPARANT is effective against CNV may help to
establish uPAR and its membrane partners as putative targets in the treatment of AMD.
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The leading cause for vision loss in the Western world isattributed to age-related macular degeneration (AMD),1 of
which neovascular AMD (nAMD) affects nearly two thirds of
advanced AMD patients.2 The imbalance in a multitude of
angiogenic and inflammatory factors, under the control of
hypoxia-dependent and -independent transcription factors,3–5
leads to choroidal neovascularization (CNV) with invasion of
the subretinal space by the newly formed vessels and leakage
from the choroid.3
Retinal pigment epithelium plays a primary role in
maintaining the outer blood retinal barrier (oBRB), and RPE
cells are a major source of angiogenic and inflammatory
factors.3 Among these, VEGF plays a crucial role in CNV, and
the recent availability of anti-VEGF drugs has represented a step
forward in the treatment of nAMD.6 However, the systemic
safety of repeated injections may pose some concerns,7 and the
long-term benefits of anti-VEGF drugs can be limited by their
loss of efficacy over time.8 In addition, the multifactorial
pathogenesis of nAMD9 may cause some resistance to anti-
VEGF therapies.10 Thus, the identification of therapeutic
approaches targeting novel pathways is actively pursued by
basic research.11
Among several pathways known to be involved in angio-
genic processes, the system formed by urokinase-type plasmin-
ogen activator (uPA) and its receptor (uPAR) is particularly
attractive as it is a major player in VEGF-induced angiogenesis.12
Interestingly, uPA and uPAR are localized to RPE and endothelial
cells of the choroid.13,14 In addition, the uPAR system is
upregulated in rodent models of CNV, and its inhibition by
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uPAR antagonists reduces CNV,14–16 although the underlying
mechanisms are not well understood.
Being devoid of intracellular domains, uPAR activates
intracellular signaling cascades by lateral interactions with
other components of the cellular membrane, including formyl
peptide receptors (FPRs).17 Formyl peptide receptors belong
to a family of transmembrane G protein–coupled receptors that
regulate the production of angiogenic and inflammatory
factors through the modulation of transcription factors
including hypoxia-inducible factor (HIF)-1, signal transducer
and activator of transcription factor 3 (STAT3), nuclear factor
kB (NF-kB), and cAMP response element binding protein
(CREB).18–20
Among peptide inhibitors of uPAR, the tetrapeptide Ac-L-
Arg-Aib-L-Arg-L-Ca(Me)Phe-NH2, named UPARANT, displays
lasting resistance to enzymatic digestion and high stability in
blood and plasma; it strongly inhibits endothelial cell migration
and proliferation by interfering with the complex cross talk
between uPAR and FPRs.21 In vitro, UPARANT reduces
capillary sprout formation, whereas in vivo, it inhibits VEGF-
induced vascularization in a rabbit corneal pocket assay and
recovers retinal neovascularization, inner BRB leakage, and
visual dysfunction in a mouse model of oxygen-induced
retinopathy (OIR).21,22
In the current study, we addressed UPARANT’s efficacy in a
mouse model of laser-induced CNV. In this model, a thermal
insult disrupts Bruch’s membrane, allowing for an ingrowth of
newly formed choroidal blood vessels into the subretinal
compartment.23,24 The laser-induced CNV model is one of the
best models currently used to mimic the pathologic mecha-
nisms in nAMD, although some differences in the chorioretinal
environment and in the disease state (acute versus chronic)
have been evidenced between mice and humans.25 In the
mouse model, we evaluated the effectiveness of UPARANT in
inhibiting laser-induced CNV. In addition, we evaluated uPAR
pathway involvement in CNV and whether the effects of
UPARANT are mediated through the uPA/uPAR system. Finally,
we assessed the effects of UPARANT on transcription factors
involved in angiogenesis and inflammation and their markers.
Overall, our data demonstrate that UPARANT is effective
against CNV and suggest the uPAR system as a putative target
in the treatment of nAMD.
MATERIALS AND METHODS
The PBS was from Gibco (Paisley, UK). Bevacizumab and the
protease and the phosphatase inhibitor cocktails were
obtained from Roche Applied Science (Indianapolis, IN,
USA). The recombinant mouse VEGF-R1/Flt-1 Fc chimera
protein was from R&D Systems (Minneapolis, MN, USA). The
RNeasy Mini, QuantiTect Reverse Transcription, and SYBR
Green PCR kits were purchased from Qiagen, Inc. (Valencia,
CA, USA). The primary antibody directed to CD31 was
obtained from BD Biosciences Pharmingen (San Diego, CA,
USA). The secondary antibody Alexa Fluor 546 was from
Molecular Probes (Eugene, OR, USA). The primary antibodies
(Supplementary Table S1) and the horseradish peroxidase
(HRP)–conjugated secondary antibodies were from Santa Cruz
Biotechnologies, Inc. (Santa Cruz, CA, USA). Polyvinylidene
difluoride (PVDF) membranes were obtained from Bio-Rad
Laboratories, Inc. (Hercules, CA, USA). The enhanced chemi-
luminescence reagent was from Millipore Corp. (Billerica, MA,
USA). The ELISA kit for the detection of uPA was from LifeSpan
BioSciences (Seattle, WA, USA). All other chemicals, including
primary antibody directed to b-actin, were obtained from
Sigma-Aldrich Corp. (St. Louis, MO, USA).
UPARANT Succinate
The angiogenesis inhibitor UPARANT, Ac-Arg-Aib-Arg-
a(Me)Phe-NH2, CAS NR 1006388-38-0, was synthesized as
previously described.21 Recently, it was produced as succinate
salt (Boccelli S, unpublished data, 2015) that was used in the
present study. Composition of the test item was peptide
content of 78.6% (as 100%  [succinate þ acetate þ water]%);
succinic acid content 17.6%; acetic acid content 0.85%; water
content 2.9%. Purity assessment by RP-HPLC was 99.3%. Each
individual unknown impurity was <0.5%. Sum of total
impurities was 0.7%. For simplicity, UPARANT succinate, used
in this work, will be henceforth referred to as UPARANT.
Animals and CNV Induction
Choroidal neovascularization lesions were induced in 6- to 8-
week-old C57BL/6J mice (Charles River, Cologne, Germany) as
previously described.23 Thirty-seven mice underwent four
lesions per eye for immunohistochemical studies, and 63 mice
nine lesions per eye for molecular studies. On day 15 after CNV
lesion induction, mice were euthanized and both eyes
enucleated and cleared from surrounding tissues. All animals
were treated in accordance with the ARVO Statement for the
Use of Animals in Ophthalmic and Vision Research, and
Stockholm’s Committee for Ethical Animal Research approved
all study protocols.
Pharmacologic Treatments
On day four after induction of CNV, mice were randomly
distributed into three groups, and both eyes were intravitreally
injected with 1 lL of vehicle (PBS) or UPARANT (dissolved in
PBS) at both 4 mg mL1 and 12 mg mL1. For clarity, UPARANT
concentrations in succinate salt are equivalent to 9.43 and 3.14
mg mL1 of active UPARANT peptide. All mice were
subsequently treated according to their grouping on days 4,
8, and 12 after laser induction.
To compare the effects of UPARANT with those of anti-
VEGF drugs, bevacizumab (1 lL) at 1.25 mg mL1 and a
recombinant mouse VEGF-R1 Fc chimera protein (1 mg mL1,
1 lL) were intravitreally injected in both eyes of mice with four
laser CNV lesions, following the same treatment scheme as
used for UPARANT.
Immunohistochemistry
Immunohistochemistry for CD31, an endothelial cell marker,
was performed on flattened RPE-choroid complexes 15 days
after laser exposure. Briefly, eyeballs were fixed overnight in
4% paraformaldehyde in 0.1 M phosphate buffer (PB),
transferred to 25% sucrose in 0.1 M PB, and stored at 48C.
Fixed eyes were dissected at the equator to obtain posterior
sclerochoroidal eyecups, and the neural retina was removed.
The RPE-choroid complexes were rinsed in 0.1 M PB and
incubated for 72 hours at 48C in rat anti-mouse CD31 (1:50 in
0.1 M PB containing 0.5% Triton X-100). The RPE-choroidal
complexes were incubated subsequently for 48 hours at 48C
with Alexa Fluor 546–conjugated secondary antibody (1:200 in
0.1 M PB) followed by rinsing in 0.1 M PB. Four radial incisions
were made in the RPE-choroid-sclera complexes, flat-mounted
on gelatin-coated glass slides, and coverslipped with a 0.1 M
PB-glycerin mixture. Images of the tissue samples were
acquired with a microscope equipped with epifluorescence
(Eclipse E800; Nikon, Amsterdam, The Netherlands) through a
digital photocamera (DS-Fi1c; Nikon). An image-editing soft-
ware (Adobe Photoshop CS3; Adobe Systems, Inc., Mountain
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View, CA, USA) was used to measure the size of hyper-
fluorescent areas corresponding to CNV lesions.
Extravasation Assay
Mice with nine lesions per eye (or control mice) were
anesthetized using ketamine (90 mg kg1) and xylazine (15
mg kg1). Five hundred microliters of Evans blue dye (0.5% in
PBS) were injected into the left ventricle of each animal and
allowed to circulate for 10 minutes. The animals were
euthanized, and the eyes were dissected from the surrounding
tissues. The dye content of the eyes was then extracted by
formamide overnight at 658C and read at 620 nm using a plate
reader (Infinite F200; Tecan Trading AG, Gro¨dig, Austria).
Quantitative RT-PCR
Eyeballs used in molecular studies (quantitative RT-PCR, ELISA,
and Western blot analysis) were immediately microdissected to
obtain RPE-choroid complexes, frozen in liquid nitrogen, and
stored at808C until use. To perform quantitative real-time RT-
PCR (qPCR) experiments, three samples, each containing one
RPE-choroid complex, were used for each experimental
condition. Total RNA was extracted using an isolation kit
(RNeasy Mini Kit; Qiagen, Inc.), purified, resuspended in
RNase-free water, and quantified using a fluorometer (Invitro-
gen, Carlsbad, CA, USA). First-strand cDNA was generated from
1 lg total RNA (Qiagen, Inc.).
Gene expression was evaluated using an SYBR Green PCR
Kit (Qiagen, Inc.). Quantitative real-time RT-PCR primer sets for
oBRB markers, the uPA/uPAR/FPR system, angiogenic factors,
and inflammatory markers were chosen to hybridize to unique
regions of the appropriate gene sequence (Supplementary
Table S2 for complete list of assayed genes and primers).
Amplification efficiency was close to 100% for each primer pair
(Opticon Monitor 3 software; Bio-Rad Laboratories, Inc.).
Target genes were assayed concurrently with ribosomal protein
(Rp)L13a, a constitutively expressed gene encoding a ribosom-
al protein. Samples were compared using the relative threshold
cycle (Ct method). The increase or decrease (fold change) was
determined relative to control mice after normalization to
RpL13a. All reactions were performed in triplicate.
Enzyme-Linked Immunosorbent Assay
Quantification of uPA protein levels was determined in protein
extracts containing soluble proteins also used for Western blot
analysis (see below). The ELISA plate was evaluated spectro-
photometrically (Microplate Reader 680 XR; Bio-Rad Laborato-
ries, Inc.). Data were expressed as picograms of uPA per
milligram of protein. All experiments were run in duplicate.
Western Blot Analysis
To perform Western blot experiments, three samples, each
containing two RPE-choroid complexes from two independent
mice, were used for each experimental condition. Retinal
pigment epithelium–choroid complexes were sonicated in 10
mM Tris-HCl (pH 7.6) containing 5 mM EDTA, 3 mM EGTA, 250
mM sucrose, and protease and phosphatase inhibitor cocktails
and were centrifuged at 22,000g for 30 minutes at 48C. The
supernatants, containing cytosolic and interstitial proteins,
were used to detect soluble proteins. Membrane-bound
proteins were isolated from the pellets by resuspension in 20
mM HEPES, pH 7.4, containing 150 mM NaCl, 5 mM EDTA, 3
mM EGTA, 4 mg mL1 n-dodecyl-b-maltoside, protease and
phosphatase inhibitor cocktails and were clarified by centrifu-
gation at 22,000g for 30 minutes at 48C. Protein concentration
was determined using a fluorometer (Qubit; Invitrogen).
Aliquots of each sample containing equal amounts of protein
(30 lg) were subjected to SDS-PAGE, and b-actin was used as
the loading control. The gels were transblotted onto PVDF
membrane, and the blots were blocked in 3% skim milk for 1
hour at room temperature, followed by incubation overnight at
48C with antibodies as indicated in Supplementary Table S1.
Finally, blots were incubated for 1 hour at room temperature
with HRP-conjugated secondary antibodies (1:5000) and
developed with enhanced chemiluminescence reagent. Images
were acquired (ChemiDoc XRSþ; Bio-Rad Laboratories, Inc.),
and optical density (OD) of the bands was evaluated (Image
Lab 3.0 software; Bio-Rad Laboratories, Inc.). The data were
normalized to the corresponding OD of b-actin, STAT3, NF-kB,
or CREB, as appropriate. All experiments were performed in
duplicate.
Data Analysis
Statistical significance was evaluated using ANOVA, followed
by Newman-Keuls multiple comparison posttest. The results
are expressed as mean 6 SEM of the indicated n values (Prism
5; GraphPad Software, San Diego, CA, USA). Differences with P
< 0.05 were considered significant.
RESULTS
UPARANT Mitigates CNV
In preliminary experiments, we evaluated maximum tolerated
dose (MTD) to determine UPARANT toxicity (Supplementary
Fig. S1). Evidence of abnormalities in the choroid, RPE, or
retina were observed at 108 mg mL1. Such data indicated that
doses of 4 and 12 mg mL1 would be considerably below the
MTD for UPARANT after intravitreal injection. In addition,
evaluation of transcript levels of apoptotic markers displayed
no elevation in laser-induced CNV eyes with doses of both 4
and 12 mg mL1 (Supplementary Fig. S1). In agreement, we
opted to perform the following experiments using the doses
below the extrapolated MTD.
In order to evaluate choroidal angiogenesis, blood vessels
were immunostained with CD31. For this purpose, the area of
CNV was quantified in flat-mounts of RPE-choroid complexes
from vehicle-treated mice and those that received UPARANT.
As compared to choroids of vehicle-treated mice (Fig. 1A), the
area of laser-induced CNV lesions was evidently reduced in
choroids of UPARANT-treated mice (Figs. 1B, 1C). Quantita-
tive analysis confirmed that UPARANT dose-dependently
reduced the CNV area (Fig. 1F). In particular, UPARANT at 4
mg mL1 reduced the CNV area by approximately 40% (P <
0.01), while UPARANT at 12 mg mL1 reduced the CNV area
by approximately 60% (P < 0.001).
To evaluate the effectiveness of UPARANT in respect to that
of anti-VEGF drugs known to be effective in mouse models of
CNV and OIR,26–28 we compared the effects of UPARANT on
the CNV area with those of either bevacizumab (1.25 mg mL1;
Fig. 1D) or a recombinant mouse VEGF-R1 Fc chimera protein
(1 mg mL1; Fig. 1E). As shown in Figure 1F, the effects of anti-
VEGF drugs on CNV did not differ from those of UPARANT at 4
mg mL1, yet were considerably elevated when compared to
UPARANT at 12 mg mL1. In particular, the CNV area was
reduced by bevacizumab and the recombinant mouse VEGF-R1
Fc chimera protein by approximately 36% and 47%, respec-
tively (P < 0.01), when compared to a range reduction of CNV
area by 60% after UPARANT treatment at 12 mg mL1.
Breakdown of the oBRB29 and albumin extravasation due to
reduced levels of barrier proteins30 have been associated with
UPARANT Mitigates Angiogenesis in Mouse CNV IOVS j May 2016 j Vol. 57 j No. 6 j 2588
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/935270/ on 05/12/2016
CNV. As shown in Figure 2A, UPARANT dose-dependently
reduced laser-induced leakage from the choroid as evaluated by
quantitative assessment of Evans blue dye extravasation. Evans
blue dye leakage was increased by approximately 2.0-fold (P <
0.05) by laser treatment, and 4 mg mL1 UPARANT prevented
this increase. Notably, 12 mg mL1 UPARANT reduced Evans blue
dye leakage to a level close to 12% lower than that in controls (P
< 0.05). Furthermore, laser treatment reduced the transcript
levels of oBRB markers31 occludin (Fig. 2B), claudin-1 (Fig. 2C),
and ZO-1 (Fig. 2D) by approximately 56% (P < 0.001), 46% (P <
0.01), and 60% (P < 0.001), respectively. After UPARANT at 4 mg
mL1, the levels of occludin, claudin-1, and ZO-1 were, in order,
approximately 34% (P < 0.01), 36% (P < 0.05), and 39% (P <
0.001) lower than controls. Markedly, 12 mg mL1 UPARANT
recovered the levels of claudin-1 to those of controls, while the
levels of occludin were approximately 15% (P < 0.05) and ZO-1
approximately 20% (P < 0.01) lower than controls.
Additionally, we assessed whether UPARANT could reach
therapeutic ocular levels after systemic administration. Using
VEGF transcripts as a marker (Supplementary Fig. S2), we
denoted that 1 mg of subcutaneously administered UPARANT
could reduce VEGF mRNA to levels comparable to 4 mg mL1
administered intravitreally. These data indicate systemic
activity of UPARANT in ocular angiogenesis.
UPARANT Does Not Directly Affect the uPA/uPAR
System
We investigated the involvement of the uPAR pathway in CNV
and whether the effects of UPARANT could be directly affecting
the uPA/uPAR system. As illustrated in Figure 3, laser treatment
did not affect uPA transcript (Fig. 3A), while it increased the level
of uPA protein (Fig. 3B) by 2.1-fold (P < 0.001). No effects of
UPARANT on uPA transcript or protein could be observed (Figs.
3A, 3B). In addition, uPAR transcript (Fig. 4A) increased in
response to laser treatment by approximately 2.1-fold and uPAR
protein (Fig. 4F) by approximately 2.5-fold (P < 0.001). Neither
FPR transcripts nor FPR proteins were affected by laser treatment
(Figs. 4B–D, 4G, 4I), with the exception of FPR2 proteins, which
were increased by 2.4-fold (Fig. 4H; P < 0.001). At none of the
doses administered was UPARANT found to influence the
expression of uPAR or FPRs at both transcript and protein levels.
Representative blots depicting the effects of UPARANT on uPA,
uPAR, and FPR at protein levels are shown in Figure 4E.
UPARANT Downregulates Levels of Transcription
Factors
The effects of UPARANT on the levels of transcription factors
involved in CNV3–5,23 were investigated. As displayed in Figure 5,
laser treatment increased the levels of HIF-1a by approximately
4.2-fold (P < 0.001) and enhanced the phosphorylation of STAT3
at Tyr705, NF-kB p65 at both Ser276 and Ser536, and CREB at Ser133
by approximately 28.6-, 6.1-, 4.4-, and 3.3-fold, respectively (P <
0.001). UPARANT reduced transcription factors with a trend
toward recovering their control levels. Upon 4 mg mL1
UPARANT, the levels of HIF-1a, pSTAT3 (Tyr705), pNF-kB p65
(Ser276), pNF-kB p65 (Ser536), and pCREB (Ser133) were
approximately 2.5- (P < 0.001), 10.0- (P < 0.01), 2.4- (P <
0.001), 2.6- (P < 0.001), and 2.1-fold (P < 0.001) higher than
those measured in controls, respectively. Upon 12 mg mL1
UPARANT, the levels of HIF-1a, pNF-kB p65 (Ser536), and pCREB
(Ser133) did not statistically differ from those measured in
controls, while the levels of pSTAT3 (Tyr705) and pNF-kB p65
(Ser276) were approximately 6.7- and 2.0-fold higher than those
measured in controls, respectively (P < 0.05). Following 12 mg
mL1 UPARANT, the levels of pSTAT3 (Tyr705) and pNF-kB p65
(Ser276) were 77% and 67% lower than in vehicle-treated mice,
respectively (P < 0.001).
FIGURE 1. UPARANT ameliorates CNV. Choroidal neovascularization was detected using an antibody directed to CD31 in flat-mounts of RPE-choroid
complexes in mice treated with vehicle (A) or with UPARANT at 4 mg mL1 (B) or 12 mg mL1 (C), and with bevacizumab at 1.25 mg mL1 (D) or a
recombinant mouse VEGF-R1 Fc chimera protein at 1 mg mL1 (E). Scale bar: 100 lm. (F) Quantitative analysis of CNV area. Bars indicate the
average CNV area in each group (*P < 0.01 and **P < 0.001 versus vehicle-treated; ANOVA). Each column represents the mean 6 SEM of data from
six RPE-choroid complexes.
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UPARANT Reduces the Expression of Angiogenic
Factors
The transcript levels of several angiogenic factors, including
VEGF, insulin-like growth factor (IGF)-1, angiopoietin (Ang)-2,
FGF-2, and platelet-derived growth factor (PDGF)-B, are
increased in mouse models of CNV.32–35 The effects of
UPARANT on angiogenic factor transcripts were investigated.
As illustrated in Figure 6, after laser treatment, the levels of
VEGF, IGF-1, Ang-2, FGF-2, and PDGF-B were increased by
approximately 1.9-, 1.6-, 2.1-, 2.1-, and 1.9-fold, respectively (P
< 0.001). UPARANT reduced angiogenic factors, with a trend
toward recovering their control levels. Specifically, after
UPARANT at 4 mg mL1, the levels of VEGF, IGF-1, Ang-2,
FIGURE 2. UPARANT reduces oBRB damage in CNV. (A) Laser-induced leakage from the choroid was evaluated by quantitative assessment of Evans
blue dye extravasation. Laser treatment increased Evans blue dye extravasation. UPARANT reduced the extravasation with a trend toward recovering
control levels. (B–D) Transcript levels of the oBRB markers occludin (B), claudin-1 (C), and ZO-1 (D) were evaluated by qPCR. Data were analyzed
by the formula 2DDCT using RpL13a as internal standard. Laser treatment decreased barrier proteins. UPARANT prevented the reduction with a
trend toward recovering control levels (*P < 0.05, **P < 0.01, and ***P < 0.001 versus control; §P < 0.05, §§P < 0.01, and §§§P < 0.001 versus
vehicle-treated; ANOVA). Data are presented as scatter plots. Each plot represents the mean 6 SEM of data from five (A) or three (B–D) independent
samples, each containing 1 RPE-choroid complex.
FIGURE 3. UPARANT does not affect uPA. (A) Transcript levels of uPA were evaluated by qPCR in RPE-choroid complexes of mice untreated or
treated with vehicle or with UPARANT at 4 or 12 mg mL1. Data were analyzed by the formula 2DDCT using RpL13a as internal standard. (B) Protein
levels of uPA were evaluated by ELISA. Laser treatment had no effects on uPA transcript, whereas it increased uPA protein. UPARANT had no effects
on uPA levels (*P < 0.001 versus control; ANOVA). Data are presented as scatter plots. Each plot represents the mean 6 SEM of data from three
independent samples, each containing one RPE-choroid complex.
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FGF-2, and PDGF-B were approximately 1.5- (P < 0.01), 1.4- (P
< 0.01), 1.9- (P < 0.001), 1.9- (P < 0.001), and 1.5-fold (P <
0.01) higher than in controls, respectively. On the other hand,
UPARANT at 12 mg mL1 recovered the levels of VEGF, FGF-2,
and PDGF-B that were not statistically different from those
measured in controls. In contrast, the levels of IGF-1 and Ang-2
were approximately 1.2- (P < 0.05) and 1.4-fold (P < 0.01)
higher than in controls, respectively, and approximately 24%
and 30% lower than in vehicle-treated, respectively (P < 0.01).
These results were further confirmed at the protein level for
VEGF, Ang-2, and FGF-2 (Supplementary Fig. S3).
UPARANT Decreases the Expression of
Inflammatory Factors
Choroidal neovascularization is characterized by an increase in
transcript levels of several inflammatory factors, including IL-
1b, IL-6, TNF-a, inducible nitric oxide synthase (iNOS),
monocyte chemotactic protein (MCP)-1, and intracellular
adhesion molecule (ICAM)-1.36–39 To evaluate the effects of
UPARANT on inflammatory factors, mRNA levels were
determined and quantified. As depicted in Figure 7, after laser
treatment, the levels of IL-1b, IL-6, TNF-a, iNOS, MCP-1, and
ICAM-1 were increased by approximately 4.7-, 2.8-, 2.6-, 2.1-,
4.0-, and 3.7-fold, respectively (P < 0.001). Similar to the
effects exerted on angiogenic factors, UPARANT reduced
inflammatory transcripts, with a trend toward recovering their
control levels. In particular, after UPARANT at 4 mg mL1, the
levels of IL-1b, IL-6, TNF-a, iNOS, MCP-1, and ICAM-1 were
approximately 3.5- (P < 0.001), 2.2- (P < 0.01), 1.6- (P < 0.01),
1.5- (P < 0.05), 3.1- (P < 0.001), and 2.9-fold (P < 0.001)
higher than in controls, respectively. Markedly, 12 mg mL1
UPARANT treatment statistically reduced the levels of TNF-a
and iNOS to those of controls, while the levels of IL-1b, IL-6,
MCP-1, and ICAM-1 were approximately 2.5- (P < 0.001), 1.7-
(P < 0.05), 2.0- (P < 0.01), and 1.7-fold (P < 0.01) higher than
in controls, respectively. These levels were approximately 46%
(P < 0.01), 39% (P < 0.01), 50% (P < 0.001), and 55% (P <
0.001) lower than in vehicle-treated mice, respectively.
DISCUSSION
In general, compared with VEGF-neutralizing antibodies or
VEGF decoy soluble receptors (VEGF-traps), peptides such as
UPARANT show several advantages, including considerably
higher activity per unit mass, greater stability, reduced
interactions with the immune system, and better tissue
permeability.40 The present study characterizes, we believe
for the first time, the effects of UPARANT in a mouse model of
laser-induced CNV that mimics the blinding disease AMD.
UPARANT reduces CNV, likely through an action at uPAR cross
talk with FPRs, by influencing transcription factors that
regulate the expression of both angiogenic and inflammatory
factors.
FIGURE 4. Regulation of uPAR and FPRs in CNV is independent of
UPARANT. Transcript levels of uPAR (A), FPR1 (B), FPR2 (C), and FPR3
(D) were evaluated by qPCR in RPE-choroid complexes of mice
untreated or treated with vehicle or with UPARANT at 4 or 12 mg mL1.
Data were analyzed by the formula 2DDCT using RpL13a as internal
standard. (E) Protein levels of uPAR and FPRs were evaluated by
Western blot using b-actin as the loading control. (F–I) Densitometric
analysis of the blots depicted in (E). Laser treatment increased uPAR
transcript and protein. Neither FPR transcripts nor FPR proteins were
affected by laser treatment with the exception of FPR2 protein.
UPARANT had no effects on uPAR or FPR levels (*P < 0.001 versus
control; ANOVA). Data are presented as scatter plots. Each plot
represents the mean 6 SEM of data from three independent samples,
each containing one (A–D) or two (F–I) RPE-choroid complexes.
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UPARANT Doses and Safety
UPARANT doses used in the present study are in the range of
those previously reported in a mouse model of OIR.22 Drugs
delivered by intravitreal injections diffuse through the vitreous
in order to reach the target tissues, being in part eliminated by
anterior and posterior routes, thus decreasing their actual
vitreal concentration.41 Therefore, when injected into the
posterior eye chamber, drugs need to be delivered at relatively
high concentrations. This requirement is not a limit in the case
of UPARANT. In fact, our results show that UPARANT MTD is
36 mg mL1 (Supplementary Fig. S1), a dose one order of
magnitude greater than the minimum effective dose used in the
present study. Safety of UPARANT is further supported by the
finding that apoptotic processes that characterize the choroid
after laser treatment42 are not significantly increased by the
drug at any concentration.
UPARANT Effects on CNV
As shown by the present results, in a mouse model of laser-
induced CNV, UPARANT ameliorates choroidal angiogenesis by
reducing the CNV area and the leakage from the choroid. These
findings further confirm the role of the uPA/uPAR system and
its interactome in regulating angiogenic processes in the
choroid.43 In this respect, previous data demonstrating that
uPA/uPAR system blockade reduces CNV not only in
rodents,14,44 but also in non-human primates,45 suggest that
this system may be a potential target to develop novel
therapeutic interventions aimed to counteract choroidal
neovascularization.
Recently, anti-VEGF drugs have been introduced to treat
CNV.46 There is evidence that VEGF acts as a major stimulator
of CNV; however, additional pathways are also known to be
involved in choroidal angiogenesis.47 Inhibition of VEGF
signaling alone is sufficient to decrease CNV, but a greater
decrease of angiogenesis may be obtained by using drugs
targeting multiple pathways,48 indicating that a pharmacologic
strategy aimed at inhibiting multiple angiogenic pathways may
be a more desirable therapeutic approach. In this respect, the
present data indicating that the multitarget molecule UPARANT
is as effective (if not superior) when compared to anti-VEGF
drugs in reducing CNV suggest that UPARANT may be of great
value in the treatment of CNV.
FIGURE 5. Downregulation of transcription factors by UPARANT. (A) Protein levels of HIF-1a, pSTAT3 (Tyr705), STAT3, pNF-kB p65 (Ser276), pNF-kB
p65 (Ser536), NF-kB p65, pCREB (Ser133), and CREB were evaluated by Western blot analysis in RPE-choroid complexes of mice untreated or treated
with vehicle or with UPARANT at 4 or 12 mg mL1. b-actin was used as the loading control. (B–F) Densitometric analysis of the blots depicted.
Protein expression was relative to the loading control b-actin (HIF-1a), to STAT3 (pSTAT3 [Tyr705]), to NF-KB p65 (pNF-kB p65 [Ser276] and pNF-kB
p65 [Ser536]) or to CREB (pCREB [Ser133]). Laser treatment increased transcription factors. UPARANT reduced transcription factors, with a trend
toward recovering control levels (*P < 0.05, **P < 0.01, and ***P < 0.001 versus control; §P < 0.001 versus vehicle-treated; ANOVA). Data are
presented as scatter plots. Each plot represents the mean 6 SEM of data from three independent samples, each containing two RPE-choroid
complexes from independent mice.
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Current anti-VEGF therapies used to counteract CNV in
nAMD, although efficacious, require prolonged treatment
regimens with frequent intravitreal injections and, consequent-
ly, carry some risks, potentially causing trauma and increasing
the incidence of cataract, retinal detachment, hemorrhage, and
endophthalmitis.49 Interestingly, we have demonstrated that
UPARANT administered by subcutaneous injection, a conve-
nient and less invasive delivery route, particularly if consider-
ing long-term use of UPARANT, is as effective as intravitreal
UPARANT in reducing VEGF levels, thus potentially inhibiting
CNV (Supplementary Fig. S2). This indicates that the drug is
taken up by the tissue from the administration site and is
conveyed to the posterior segment of the eye by blood flow,
resulting in a retinal concentration in the order of that reached
after intravitreal administration.
UPARANT Mechanism of Action in CNV
In agreement with previous studies, the present findings
demonstrate an increased expression of uPA and uPAR in the
CNV model,14,15 confirming a direct link between uPA/uPAR
upregulation and choroidal angiogenesis. In this respect, uPA
binding to uPAR causes extracellular matrix degradation,
permissive for de novo development of blood vessels.50 The
fact that uPA upregulation involves both translational and
posttranslational regulation hints at the existence of regulatory
mechanisms distinct from transcriptional activation as puta-
tively epigenetic mechanisms. In fact, several microRNAs have
been demonstrated to regulate uPA expression in humans.51,52
Upregulation of uPA/uPAR in CNV could be explained by
presupposing that RPE and choroidal endothelial cells, both
known to express uPA and uPAR,13,14 may release soluble
factors in response to the laser injury. Such factors could then
exert activity in a paracrine fashion and increase the
expression of uPA and uPAR, in turn representing the switch
to induce choroidal angiogenesis.
Urokinase-type plasminogen activator receptor cross talk
with FPRs plays a key role in physiological and pathologic
processes, thus providing insights into the potential clinical
relevance of new treatment regimens involving the uPAR/FPR
system. As shown by the present results, laser treatment
increases FPR2 proteins without affecting FPR1 and FPR3,
indicating a prominent role of FPR2 in angiogenic processes.19
In this respect, FPR2 agonism induces proliferation, migration,
and tube formation in endothelial cells and promotes
pathologic angiogenesis in in vivo models.53 However, there
is also evidence that FPR2 activation inhibits VEGF-induced
neovascularization in a mouse model of corneal angiogenesis.54
Nevertheless, in the specific case of the cornea, FPR2-mediated
activation of angiogenesis-related transcription factors (HIF-1
and STAT3) could lead to upregulation of inhibitory Per/Arnt/
Sim protein and soluble VEGFR,55,56 both well characterized as
responsible for the avascular phenotype of the cornea, by
inhibiting VEGF-dependent neovascularization in the cornea.
FIGURE 6. UPARANT downregulates angiogenic factors. Transcript levels of VEGF (A), IGF-1 (B), Ang-2 (C), FGF-2 (D), and PDGF-B (E) were
evaluated by qPCR in RPE-choroid complexes of mice untreated or treated with vehicle or with UPARANT at 4 or 12 mg mL1. Data were analyzed
by the formula 2DDCT using RpL13a as internal standard. Laser treatment increased angiogenic factors. UPARANT reduced them, with a trend
toward recovering control levels (*P < 0.05, **P < 0.01, and ***P < 0.001 versus control; §P < 0.05, §§P < 0.01, and §§§P < 0.001 versus vehicle-
treated; ANOVA). Data are presented as scatter plots. Each plot represents the mean 6 SEM of data from three independent samples, each
containing one RPE-choroid complex.
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UPARANT has been designed to mimic the sequence 88Ser-
Arg-Ser-Arg-Tyr92, through which uPAR interacts with and
activates FPRs.19 Accordingly, UPARANT competes with N-
formyl-Met-Leu-Phe (fMLF), a known FPR ligand, for binding to
FPRs. UPARANT excess prevents fMLF binding to FPRs, an
indication that fMLF and UPARANT share the same binding
site.21 The present data demonstrating that UPARANT mitigates
CNV by inhibiting HIF-1, STAT3, NF-kB, and CREB signaling
pathways, even in the presence of elevated levels of uPA,
suggest that UPARANT mitigates CNV by inhibiting FPRs-
mediated regulation of transcription factors coupled to
angiogenesis and inflammation.19,20,57 Based on these facts,
we propose a mechanism of action for UPARANT in CNV by
preventing uPAR from activating the signaling cascade
downstream of FPRs.
From a mechanistic point of view, an ischemic/inflamma-
tory insult, as observed in AMD, activates several intracellular
signaling pathways involved in promoting CNV. We hypothe-
size that, upon induction of CNV, uPA, uPAR, and FPR2 are
upregulated, resulting in increased signaling downstream of
the FPRs, leading to enhanced expression of angiogenic and
inflammatory factors. Subsequently, upregulated soluble fac-
tors promote angiogenesis and inflammation, culminating in
the pathologic state that characterizes CNV. Schematically,
Figure 8 illustrates the complex molecular process through
which UPARANT would act as an inhibitor of the interactions
between uPAR and FPRs, thus ameliorating CNV.
UPARANT Effects on Angiogenesis and
Inflammation
In the laser-induced CNV model of nAMD, the present results
demonstrate that UPARANT reduces the expression of
transcription factors, which are key regulators of the neo-
angiogenic response by mediating the production of both
angiogenic and inflammatory factors. In particular, UPARANT
action on HIF-1a and pSTAT3 described here is consistent
with data obtained in a model of proliferative retinopathy in
which UPARANT has been found to reduce their expres-
sion.22 HIF-1 and STAT3 are two key regulators of VEGF
expression.58,59 In this respect, uPAR silencing downregu-
lates VEGF expression by reducing the activity of both HIF-1
and STAT3 in glioma cells.60 In addition, HIF-1 and STAT3 also
regulate the expression of several inflammatory factors in line
with a tight cross talk between angiogenesis and inflamma-
tion.32 In this respect, the present results demonstrate that
UPARANT almost normalizes the laser-induced upregulation
of the transcription factors NF-kB and CREB that are known to
control the expression of a large number of genes under
inflammatory conditions.61 Interestingly, the fact that either
STAT3 or NF-kB may serve as a partner for HIF-1 in activating
inflammatory pathways62 suggests that cooperative relation-
ships between transcription factors may participate in the
pathogenesis of nAMD and indicates that UPARANT may
FIGURE 7. UPARANT reduces levels of inflammatory factors. Transcript levels of IL-1b (A), IL-6 (B), TNF-a (C), iNOS (D), MCP-1 (E), and ICAM-1 (F)
were evaluated by qPCR in RPE-choroid complexes of mice untreated or treated with vehicle or with UPARANT at 4 or 12 mg mL1. Data were
analyzed by the formula 2DDCT using RpL13a as internal standard. Laser treatment increased inflammatory factors. UPARANT reduced them, with a
trend toward recovering control levels (*P < 0.05, **P < 0.01, and ***P < 0.001 versus control; §P < 0.05, §§P < 0.01, and §§§P < 0.001 versus
vehicle-treated; ANOVA). Data are presented as scatter plots. Each plot represents the mean 6 SEM of data from three independent samples, each
containing one RPE-choroid complex.
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suppress the cross talk between transcription factors involved
in this pathology.
The present findings further confirm that nAMD, as many
other ocular neovascular pathologies, is a multifactorial disease
resulting from deregulation of several factors, including a
variety of proinflammatory cytokines and chemokines. In
nAMD, particularly, choroidal vessel growth is likely to be
caused by either local tissue ischemia or the presence of an
inflammatory reaction. However, a unifying model in which
local inflammation triggers neovascularization is currently the
most favored.63 Accordingly, prevention of inflammation at
early disease stages is sought as a therapeutic approach to
avoid irreversible damage to the retinal tissue.
As a consequence of UPARANT-induced reduction of
transcription factors, decreased levels of angiogenic and
inflammatory markers have been determined in the choroid,
thus indicating that uPA/uPAR/FPR activation may regulate
their expression in response to ischemic/inflammatory insult
and suggesting a causal relationship between the inhibitory
effects of UPARANT and the amelioration of pathologic
neovascularization (Fig. 8).
UPARANT, a Novel Therapy for AMD?
Previous and present data suggest that UPARANT may be
potentially therapeutic for ocular diseases characterized by
pathologic angiogenesis. In this respect, nAMD is character-
ized by largely irreversible vision impairment. In nAMD, CNV
can be treated but not cured with VEGF inhibitors. In this
respect, monthly injections of VEGF inhibitors are expensive
to the health care system and burdensome to patients.64 As
compared to the currently used drugs, which act by
abolishing VEGF bioavailability, here we demonstrate a novel
mechanism through which increased levels of VEGF can be
lowered. In fact, the present results highlight the finding that
the levels of several angiogenic/inflammatory factors other
than VEGF are reduced by UPARANT and that UPARANT
treatment acts intrinsically by normalizing the upregulated
levels of angiogenic/inflammatory factors. Taken together,
these findings suggest that UPARANT treatment, by down-
regulating key transcription factors, thus normalizing a
multitude of angiogenic and inflammatory molecules to basal
levels, could avoid possible side effects deriving from the
targeted inactivation of specific factors (e.g., anti-VEGF
therapies) necessary for physiological responses, even during
pathology.
CONCLUSIONS
The use of multitarget drugs may be an effective approach in
the treatment of CNV. The present data provide evidence that
the uPA/uPAR/FPR system and its interactome are promising
targets for the development of antiangiogenic drugs against
ocular angiogenesis. Although an extrapolation of these
experimental findings to the clinic is premature, UPARANT
may be viewed as a novel multitarget drug with potential
implications for therapeutic interventions aimed at inhibiting
the neovascular responses occurring in patients suffering from
nAMD.
Acknowledgments
Supported by grants from Italian Ministero della Salute (RF-2011-
02351158; PB; Roma, Italy), BIOOS Italia (PB; Montegiorgio, Italy);
The Crown Princess Margareta Association for the Visually
Impaired (HA; Valdemarsvik, Sweden), Edwin Jordan Foundation
(HA; Stockholm, Sweden), Tore Nilsson Foundation (HA; Stock-
holm, Sweden), The Swedish Research Council (HA; Stockholm,
Sweden), The Swedish Eye Foundation (HA; Umea˚, Sweden);
European Union–Fondi Europei per lo Sviluppo Regionale, Italian
Ministero dell’Istruzione e dell’Universita`, and Italian Ministero
dello Sviluppo Economico (PON01 02464; MDR and VP; Roma,
Italy).
Disclosure: M. Cammalleri, None; M. Dal Monte, None; F.
Locri, None; L. Lista, None; M. Aronsson, None; A. Kvanta,
None; D. Rusciano, BIOOS (E); M. De Rosa, Pharmafelix (I, P); V.
Pavone, Pharmafelix (I, P); H. Andre´, None; P. Bagnoli, None
References
1. Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual
impairment in the year 2002. Bull World Health Organ. 2004;
82:844–851.
2. Miller JW. Age-related macular degeneration revisited—piecing
the puzzle: the LXIX Edward Jackson memorial lecture. Am J
Ophthalmol. 2013;155:1–35.e13.
3. Campochiaro PA. Molecular pathogenesis of retinal and
choroidal vascular diseases. Prog Retin Eye Res. 2015;49:67–
81.
4. Hytti M, Piippo N, Salminen A, Honkakoski P, Kaarniranta K,
Kauppinen A. Quercetin alleviates 4-hydroxynonenal-induced
cytotoxicity and inflammation in ARPE-19 cells. Exp Eye Res.
2015;132:208–215.
5. Izumi-Nagai K, Nagai N, Ozawa Y, et al. Interleukin-6 receptor-
mediated activation of signal transducer and activator of
transcription-3 (STAT3) promotes choroidal neovasculariza-
tion. Am J Pathol. 2007;170:2149–2158.
FIGURE 8. Schematic diagram of the intracellular pathways linking
uPAR activation of FPRs to the production of angiogenic and
inflammatory factors. An insult (e.g., an inschemic/inflammatory
insult) upregulates uPA, uPAR, and FPR2, likely resulting in increased
interactions between uPARs and FPRs. In turn, increased downstream
FPR signaling increases the expression of angiogenic and inflammatory
factors through the activation of transcription factors. Subsequently,
upregulated soluble factors promote angiogenesis and inflammation,
culminating in the pathologic state that characterizes nAMD. UPARANT
would act as an inhibitor of these processes in preventing the
interactions between uPARs and FPRs, thus ameliorating nAMD. Green
schematics indicate upregulations, red schematics downregulations,
dashed schematics multistep pathways. AF, angiogenic factors; IF,
inflammatory factors.
UPARANT Mitigates Angiogenesis in Mouse CNV IOVS j May 2016 j Vol. 57 j No. 6 j 2595
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/935270/ on 05/12/2016
6. Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines
for the management of neovascular age-related macular
degeneration by the European Society of Retina Specialists
(EURETINA). Br J Ophthalmol. 2014;98:1144–1167.
7. Lim JI, Fung AE, Wieland M, Hung D, Wong V. Sustained-release
intravitreal liquid drug delivery using triamcinolone acetonide
for cystoid macular edema in retinal vein occlusion. Ophthal-
mology. 2011;118:1416–1122.
8. Martin DF, Maguire MG, Fine SL, et al.; for Comparison of Age-
related Macular Degeneration Treatments Trials (CATT)
Research Group. Ranibizumab and bevacizumab for treatment
of neovascular age-related macular degeneration: two-year
results. Ophthalmology. 2012;119:1388–1398.
9. Nowak JZ. AMD–the retinal disease with an unprecised
etiopathogenesis: in search of effective therapeutics. Acta
Pol Pharm. 2014;71:900–916.
10. Amoaku WM, Chakravarthy U, Gale R, et al. Defining response
to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;
29:721–731.
11. Todorich B, Yiu G, Hahn P. Current and investigational
pharmacotherapeutic approaches for modulating retinal an-
giogenesis. Expert Rev Clin Pharmacol. 2014;7:375–391.
12. Uhrin P, Breuss JM. uPAR: a modulator of VEGF-induced
angiogenesis. Cell Adh Migr. 2013;7:23–26.
13. Sugioka K, Kodama A, Okada K, et al. TGF-b2 promotes RPE
cell invasion into a collagen gel by mediating urokinase-type
plasminogen activator (uPA) expression. Exp Eye Res. 2013;
115:13–21.
14. Das A, Boyd N, Jones TR, Talarico N, McGuire PG. Inhibition of
choroidal neovascularization by a peptide inhibitor of the
urokinase plasminogen activator and receptor system in a
mouse model. Arch Ophthalmol. 2004;122:1844–1849.
15. McGuire PG, Jones TR, Talarico N, Warren E, Das A. The
urokinase/urokinase receptor system in retinal neovascular-
ization: inhibition by A6 suggests a new therapeutic target.
Invest Ophthalmol Vis Sci. 2003;44:2736–2742.
16. Rakic JM, Lambert V, Munaut C, et al. Mice without uPA, tPA,
or plasminogen genes are resistant to experimental choroidal
neovascularization. Invest Ophthalmol Vis Sci. 2003;44:1732–
1739.
17. Eden G, Archinti M, Furlan F, Murphy R, Degryse B. The
urokinase receptor interactome. Curr Pharm Des. 2011;17:
1874–1889.
18. Armbruster NS, Richardson JR, Schreiner J, et al. PSM peptides
of Staphylococcus aureus activate the p38-CREB pathway in
dendritic cells, thereby modulating cytokine production and T
cell priming. J Immunol. 2016;196:1284–1292.
19. Prevete N, Liotti F, Marone G, Melillo RM, de Paulis A. Formyl
peptide receptors at the interface of inflammation, angio-
genesis and tumor growth. Pharmacol Res. 2015;102:184–
191.
20. Cattaneo F, Guerra G, Ammendola R. Expression and signaling
of formyl-peptide receptors in the brain. Neurochem Res.
2010;35:2018–2026.
21. Carriero MV, Bifulco K, Minopoli M, et al. UPARANT: a
urokinase receptor-derived peptide inhibitor of VEGF-driven
angiogenesis with enhanced stability and in vitro and in vivo
potency. Mol Cancer Ther. 2014;13:1092–1104.
22. Dal Monte M, Rezzola S, Cammalleri M, et al. Antiangiogenic
effectiveness of the urokinase receptor-derived peptide
UPARANT in a model of oxygen-induced retinopathy. Invest
Ophthalmol Vis Sci. 2015;56:2392–2407.
23. Andre´ H, Tunik S, Aronsson M, Kvanta A. Hypoxia-inducible
factor-1a is associated with sprouting angiogenesis in the
murine laser-induced choroidal neovascularization model.
Invest Ophthalmol Vis Sci. 2015;56:6591–6604.
24. Kvanta A. Ocular angiogenesis: the role of growth factors. Acta
Ophthalmol. 2006;84:282–288.
25. Shah RS, Soetikno BT, Lajko M, Fawzi AAA. A Mouse model for
laser-induced choroidal neovascularization. J Vis Exp. 2015;
doi:10.3791/53502.
26. Hollanders K, Van Bergen T, Van de Velde S, et al. Bevacizumab
revisited: its use in different mouse models of ocular
pathologies. Curr Eye Res. 2015;40:611–621.
27. Feng F, Cheng Y, Liu QH. Bevacizumab treatment reduces
retinal neovascularization in a mouse model of retinopathy of
prematurity. Int J Ophthalmol. 2014;7:608–613.
28. Liu H, Zhang W, Xu Z, Caldwell RW, Caldwell RB, Brooks SE.
Hyperoxia causes regression of vitreous neovascularization by
downregulating VEGF/VEGFR2 pathway. Invest Ophthalmol
Vis Sci. 2013;54:918–931.
29. Wittchen ES, Nishimura E, McCloskey M, et al. Rap1 GTPase
activation and barrier enhancement in RPE inhibits choroidal
neovascularization in vivo. PLoS One. 2013;8:e73070.
30. Ijima R, Kaneko H, Ye F, et al. Interleukin-18 induces retinal
pigment epithelium degeneration in mice. Invest Ophthalmol
Vis Sci. 2014;55:6673–6678.
31. Hartsock A, Nelson WJ. Adherens and tight junctions:
structure, function and connections to the actin cytoskeleton.
Biochim Biophys Acta. 2008;1778:660–669.
32. de Oliveira Dias JR, Rodrigues EB, Maia M, Magalha˜es O Jr,
Penha FM, Farah ME. Cytokines in neovascular age-related
macular degeneration: fundamentals of targeted combination
therapy. Br J Ophthalmol. 2011;95:1631–1637.
33. Yang SJ, Jo H, Kim JG, Jung SH. Baicalin attenuates laser-
induced choroidal neovascularization. Curr Eye Res. 2014;39:
745–751.
34. Rennel ES, Regula JT, Harper SJ, Thomas M, Klein C, Bates DO.
A human neutralizing antibody specific to Ang-2 inhibits
ocular angiogenesis. Microcirculation. 2011;18:598–607.
35. Qu Y, Zhang S, Xu X, et al. Octreotide inhibits choroidal
neovascularization in rats. Ophthalmic Res. 2009;42:36–42.
36. Zhang H, Yang Y, Takeda A, et al. A novel platelet-activating
factor receptor antagonist inhibits choroidal neovasculariza-
tion and subretinal fibrosis. PLoS One. 2013;8:e68173.
37. Xie P, Zhang W, Yuan S, et al. Suppression of experimental
choroidal neovascularization by curcumin in mice. PLoS One.
2012;7:e53329.
38. Lavalette S, Raoul W, Houssier M, et al. Interleukin-1b
inhibition prevents choroidal neovascularization and does
not exacerbate photoreceptor degeneration. Am J Pathol.
2011;178:2416–2423.
39. She H, Nakazawa T, Matsubara A, et al. Reduced photoreceptor
damage after photodynamic therapy through blockade of
nitric oxide synthase in a model of choroidal neovasculariza-
tion. Invest Ophthalmol Vis Sci. 2007;48:2268–2277.
40. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic
therapeutic peptides: science and market. Drug Discov Today.
2010;15:40–56.
41. Urtti A. Challenges and obstacles of ocular pharmacokinetics
and drug delivery. Adv Drug Deliv Rev. 2006;58:1131–1135.
42. Du H, Sun X, Guma M, et al. JNK inhibition reduces apoptosis
and neovascularization in a murine model of age-related
macular degeneration. Proc Natl Acad Sci U S A. 2013;110:
2377–2382.
43. Das A, McGuire P. Role of urokinase inhibitors in choroidal
neovascularization. Semin Ophthalmol. 2006;21:23–27.
44. Koh HJ, Bessho K, Cheng L, et al. Inhibition of choroidal
neovascularization in rats by the urokinase-derived peptide
A6. Invest Ophthalmol Vis Sci. 2004;45:635–640.
45. Koh HJ, Freeman WR, Azen SP, et al. Effect of a novel
octapeptide urokinase fragment, A6, on experimental choroi-
dal neovascularization in the monkey. Retina. 2006;26:202–
209.
UPARANT Mitigates Angiogenesis in Mouse CNV IOVS j May 2016 j Vol. 57 j No. 6 j 2596
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/935270/ on 05/12/2016
46. Amadio M, Govoni S, Pascale A. Targeting VEGF in eye
neovascularization: what’s new?: a comprehensive review on
current therapies and oligonucleotide-based interventions
under development. Pharmacol Res. 2016;103:253–269.
47. van Lookeren Campagne M, LeCouter J, Yaspan BL, Ye W.
Mechanisms of age-related macular degeneration and thera-
peutic opportunities. J Pathol. 2014;232:151–164.
48. Das RA, Romano A, Chiosi F, Menzione M, Rinaldi M.
Combined treatment modalities for age related macular
degeneration. Curr Drug Targets. 2011;12:182–189.
49. Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to
retinal drug delivery. Expert Opin Drug Deliv. 2007;4:371–388.
50. Montuori N, Ragno P. Role of uPA/uPAR in the modulation of
angiogenesis. Chem Immunol Allergy. 2014;99:105–122.
51. Li C, Zhu HY, Bai WD, et al. MiR-10a and miR-181c regulate
collagen type I generation in hypertrophic scars by targeting
PAI-1 and uPA. FEBS Lett. 2015;589:380–389.
52. Li J, Kong F, Wu K, Song K, He J. Sun W. miR-193b directly
targets STMN1 and uPA genes and suppresses tumor growth
and metastasis in pancreatic cancer. Mol Med Rep. 2014;10:
2613–2620.
53. Lee MS, Yoo SA, Cho CS, Suh PG, Kim WU, Ryu SH. Serum
amyloid A binding to formyl peptide receptor-like 1 induces
synovial hyperplasia and angiogenesis. J Immunol. 2006;177:
5585–5594.
54. Leedom AJ, Sullivan AB, Dong B, Lau D, Gronert K.
Endogenous LXA4 circuits are determinants of pathological
angiogenesis in response to chronic injury. Am J Pathol. 2010;
176:74–84.
55. Makino Y, Cao R, Svensson K, et al. Inhibitory PAS domain
protein is a negative regulator of hypoxia-inducible gene
expression. Nature. 2001;414:550–554.
56. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is
due to soluble VEGF receptor-1. Nature. 2006;443:993–997.
57. Shin MK, Jang YH, Yoo HJ, et al. N-formyl-methionyl-leucyl-
phenylalanine (fMLP) promotes osteoblast differentiation via
the N-formyl peptide receptor 1-mediated signaling pathway
in human mesenchymal stem cells from bone marrow. J Biol
Chem. 2011;286:17133–17143.
58. Chen Z, Han ZC. STAT3: a critical transcription activator in
angiogenesis. Med Res Rev. 2008;28:185–200.
59. Fong GH. Regulation of angiogenesis by oxygen sensing
mechanisms. J Mol Med. 2009;87:549–560.
60. Malla RR, Gopinath S, Gondi CS, et al. Cathepsin B and uPAR
knockdown inhibits tumor-induced angiogenesis by modulat-
ing VEGF expression in glioma. Cancer Gene Ther. 2011;18:
419–434.
61. Newton K, Dixit VM. Signaling in innate immunity and
inflammation. Cold Spring Harb Perspect Biol. 2012;4(3):
a006049.
62. Balamurugan K. HIF-1 at the crossroads of hypoxia, inflam-
mation, and cancer. Int J Cancer. 2015;138:1058–1066.
63. Tezel TH, Bora NS, Kaplan HJ. Pathogenesis of age-related
macular degeneration. Trends Mol Med. 2004;10:417–420.
64. Day S, Acquah K, Lee PP, Mruthyunjaya P, Sloan FA. Medicare
costs for neovascular age-related macular degeneration, 1994–
2007. Am J Ophthalmol. 2011;152:1014–1020.
UPARANT Mitigates Angiogenesis in Mouse CNV IOVS j May 2016 j Vol. 57 j No. 6 j 2597
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/935270/ on 05/12/2016
